LY-N001 (Lingyi Biotech)

N/A

Report date: 2025/06/11 10:49:25

Base Information

Drug NameLY-N001 (Lingyi Biotech)
Drug Alias NameGBA1 gene therapy (Lingyi Biotech)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionBeta-glucocerebrosidase stimulants
TargetsBeta-glucocerebrosidase
Therapy Area/IndicationsNerve DegenerationParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesLingyi Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLingyi Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsNerve DegenerationParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A